CA-XPRIZE
XPRIZE , the global leader in incentivized prize competitions, in partnership with ANA , Japan’s 5-star airline, announce Avatars Inc , a unique online anthology that blends original science fiction stories with a writing competition to imagine novel use-cases of telepresence technology in the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005209/en/
The anthology, edited by Ann VanderMeer, includes 24 original pieces by high-profile authors including James SA Corey, Adrian Tchaikovsky, Tade Thompson, Pat Cadigan, JY Yang, Ken Liu, Charles Yu, Paul McAuley, K Chess, Johanna Sinisalo, and Aliette de Bodard.
The premise for the anthology is as follows:
Established in 2038, Avatars Inc is the world’s leading producer of robotic avatar systems that can transport a human’s senses, actions, and presence to a remote location in real time. For the next few decades, they developed hundreds of avatar models and enabled millions of operator-hours. In 2080, a campaign was underway to physically retrieve, preserve and archive the memories from their most valuable units. We have been searching the world, and even deep into the solar system, to acquire the chips that contain avatar memories spanning the 21st century. These are those memories.
The short story contest is open through May 8, 2020 and is open to anyone over the age of 18 who submits an original story between 2,500 – 3,500 words, bringing to life a ‘missing’ avatar memory. Members of XPRIZE’s Science Fiction Advisory Council will vote on the finalist pieces to select the grand prize winner, who will then receive a prize package including a 3.2GHz 8-core Intel Xeon W Processor iMac Pro, a GoPro Hero7 Camera, Sony noise cancelling headphones, a 32GB Kindle Paperwhite, a JoneR Universal Translator, and more.
The fictional Avatars Inc was inspired by the real-life $10 million ANA Avatar XPRIZE , a four-year global competition focused on the development of an avatar system that can transport a human’s senses, actions, and presence to a remote location in real time. The competition was launched in March 2018 at South by Southwest (SXSW) in Austin.
“The world of Avatars Inc was made possible by the incredible partnership between XPRIZE and ANA and is intended to elevate the overall conversation about avatars among the general public, making the topic of avatars accessible, relevant and exciting, while creating demand and interest in the technologies that will result from the ANA Avatar XPRIZE,” said David Locke, Prize Lead of the ANA Avatar XPRIZE.
As of January 2020, a total of 77 teams from 19 countries qualified to compete. In March 2022, up to 20 teams will compete in the finals, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use-case scenarios. The first-place winner will receive $5 million.
To explore the world of Avatars Inc, and to submit your short story, visit http://www.avatars.inc .
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005209/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom